My NCBISign In
Clinical review: Drotrecogin alfa (activated) as adjunctive therapy for severe sepsis – practical aspects at the bedside and patient identification
Pierre-François Laterre, Xavier Wittebole
Crit Care. 2003; 7(6): 445–450. Published online 2003 June 30. doi: 10.1186/cc2342
PMCID:
PMC374360
Abstract Full Text PDF–65K

Is Cited by the Following 4 Articles in this Archive:

Early drotrecogin alpha (activated) administration in severe sepsis is associated with lower mortality: a retrospective analysis of the Canadian ENHANCE cohort
Richard V Hodder, Richard Hall, James A Russell, Harold N Fisher, Bobbie Lee
Crit Care. 2009; 13(3): R78. Published online 2009 May 20. doi: 10.1186/cc7893
PMCID:
PMC2717441
Abstract Full Text PDF–152K
Low-Dose, Off-Label Drotrecogin Alfa (Xigris) In Severe Sepsis
Shan Wang, Kristina Dabovic, Ruth S. Spector
P T. 2008 August; 33(8): 469-472, 475-476.
PMCID:
PMC2730102
Abstract Full Text PDF–187K
The safety profile of drotrecogin alfa (activated)
Roberto Fumagalli, Mariano A Mignini
Crit Care. 2007; 11(Suppl 5): S6. Published online 2007 December 19. doi: 10.1186/cc6157
PMCID:
PMC2230610
Abstract Full Text PDF–67K
Practical aspects of treatment with drotrecogin alfa (activated)
Luigi Camporota, Duncan Wyncoll
Crit Care. 2007; 11(Suppl 5): S7. Published online 2007 December 19. doi: 10.1186/cc6158
PMCID:
PMC2230611
Abstract Full Text PDF–76K
You are here: NCBI > Literature > PubMed Central (PMC)
Write to the Help Desk